|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
SP Mulligan, P Travade, E Matutes, C Dearden, L Visser, S Poppema and D Catovsky
Academic Department of Haematology and Cytogenetics, Royal Marsden
Hospital, London, UK.
We undertook a study to determine the specificity of the monoclonal
antibody, B-ly-7, for hairy cell leukemia (HCL) by examining the expression
in 150 samples from B-cell lymphoproliferative diseases as well as
screening for reactivity in a number of other hematologic malignancies.
Within the B-cell lineage we found that the expression of B-ly-7 was highly
specific for HCL and reacted with all 28 cases examined, as well as with 3
of 9 cases of a variant form of HCL. Cells of other closely related B-cell
disorders, prolymphocytic leukemia, and splenic lymphoma with villous
lymphocytes were negative. Investigation of the peripheral blood and bone
marrow of patients with HCL before and after treatment with
alpha-interferon or deoxycoformycin suggests that B-ly-7 may be useful in
the assessment of minimal disease after therapy. In addition to HCL, we
found that B-ly-7 was positive with cells of three mature, CD4+ T-cell
malignancies. In view of the reactivity with malignancies of activated B
and T cells, we searched for the expression of B-ly-7 on activated, normal
B and T cells and found that B-ly-7 reacted specifically with activated
normal peripheral blood CD8+ T cells. B-ly-7 has a number of applications,
including the precise classification of mature B-cell neoplasia and the
diagnosis HCL and its assessment after treatment. In addition, B-ly-7
recognizes a small subset of T-cell disorders. Its expression on these
malignancies and on in vitro activated peripheral blood CD8+ T cells
suggests that B- ly-7 detects a lymphocyte activation antigen.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1990 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
